EN
Instrument Fundamentals
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
News
BlackLine Honors Global Enterprise Leaders Transforming Financial Operations
Bristol Myers Squibb (BMY) Stock May Be Undervalued Despite Fresh Phase 3 Trial Wins
Bristol Myers Squibb (NYSE:BMY) Stock Price Target Cut by Wells Fargo & Company - Daily Political
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Bristol-Myers Squibb (BMY) and Palvella Therapeutics (PVLA)
Health Care Up Amid Deal Activity - Health Care Roundup | Morningstar
BMY's RYZ101 Meets Phase 3 Goal, Improving PFS In Advanced GEP-NETs
Bristol Myers dips on 'confounding' lung drug results
13 New 4-Star Stocks This Week | Morningstar
Bristol Myers Squibb Reports Positive Phase 3 Results For Admilparant In IPF
Bristol-Myers Squibb Announces Positive Topline Data From RYZ101 Study, Stock Up In Pre-Market
Bristol Myers' Phase 3 Trial Of Admilparant In Idiopathic Pulmonary Fibrosis Met Primary Endpoint
Bristol Myers Squibb Treatment Meets Primary Endpoint in Phase 3 Trial for Idiopathic Pulmonary Fibrosis | Morningstar
Bristol Myers Squibb stock surges on dual phase 3 clinical trial successes
Bristol Myers cancer therapy meets main goal in late-stage study
Bristol Myers Squibb (NYSE:BMY) and Takeda Pharmaceutical (NYSE:TAK) Financial Review - Zolmax
Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint | Morningstar
NSCLC Pipeline 2026: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | AbbVie, Xcovery, Sanofi, Pfizer, Mirati Therapeutics, AstraZeneca, Daiichi Sankyo, Merck | ABNewswire
Bristol Myers Squibb (NYSE:BMY) Stock Gets Price Target Trim from Cantor Fitzgerald - Stock Observer
Bristol Myers Squibb Company $BMY Holdings Lessened by RTD Financial Advisors Inc. - Markets Daily
20,370 Bristol Myers Squibb Company $BMY Shares Bought by Apella Capital LLC
Bristol Myers Squibb Company $BMY Shares Sold by RTD Financial Advisors Inc. - Stock Observer
Bank of America Cuts Bristol Myers Squibb (NYSE:BMY) Price Target to $66.00
Bristol Myers Squibb (NYSE:BMY) Stock Price Target Raised at Rothschild & Co Redburn
53,744 Bristol Myers Squibb Company $BMY Shares Sold by Douglas Lane & Associates LLC
Bristol Myers Squibb (NYSE:BMY) Stock Price Target Lowered at Bank of America - Daily Political
Bristol Myers Squibb Company $BMY Stock Bought by Monument Capital Management
Bristol Myers Squibb Company $BMY Shares Acquired by Mn Services Vermogensbeheer B.V.
11,617 Bristol Myers Squibb Company $BMY Shares Bought by Monument Capital Management - Stock Observer
Quintet Private Bank Europe S.A. Lowers Holdings in Bristol Myers Squibb Company $BMY - Markets Daily
Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?
Bristol Myers Squibb Company $BMY Stock Sold by Quintet Private Bank Europe S.A. - Stock Observer
Bristol Myers Squibb (NYSE:BMY) Stock Price Target Lowered at Cantor Fitzgerald - Markets Daily
BMY Maintains Rating by Morgan Stanley -- Price Target Raised to
5 Dividend Stocks With Fortress-Like Coverage and Room for Things to Go Wrong
Bristol Myers Squibb (BMY) Expands CAMZYOS Approval, Is The Stock Still A Bargain?
Takeda's zasocitinib raises bar for oral psoriasis drugs
Bristol Myers Squibb (NYSE:BMY) Stock Rating Cut to Market Perform at Leerink Partners - Markets Daily
Bristol Myers (BMY) Stock is Trading Below 10 Times Forward Earnings. Here's Why it Matters - Insider Monkey
Top Pharmaceutical Stocks To Follow Now - October 5th - Markets Daily
Top Pharmaceutical Stocks To Follow Now - October 5th - Stock Observer
Pfizer's Turnaround Could Be Bigger Than Investors Think, Set For 20% Upside
Bristol Myers Squibb Deepens Commitment to Healthcare
AbbVie (ABBV) vs Bristol Myers (BMY): Which is a Better Stock to Buy?
CX Institutional Sells 208,135 Shares of Bristol Myers Squibb Company $BMY
Eli Lilly & Co (LLY) Gets a Buy from RBC Capital
BMY Stock Gets Stronger EPS Forecast from Zacks Research - Daily Political
Urine cell-free RNA for bladder cancer detection and treatment response prediction
Analysts unshaken by patient death in BMS lung fibrosis trial
BMY: Legacy Drug Erosion Looms, Oncology Platforms And AI Hold The Upside
RBC Capital Keeps Their Hold Rating on Merck & Company (MRK)
What is Johnson & Johnson's (JNJ) Economic Moat, and is it Widening or Narrowing?
Heparin-Induced Thrombocytopenia Market: Steady Growth Driven by Emerging Non-Heparin Anticoagulants and Novel Therapies by 2034 | ABNewswire
"There is growing emphasis on B-cell maturation antigen-targeted cell therapies to treat Multiple Myeloma"
Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
Bristol Myers Squibb Says FDA Approves Heart Disease Treatment Camzyos for Pediatric Patients | Morningstar
Promising Pharmaceutical Stocks Worth Watching - September 30th
Bristol Myers Squibb's Dividend Sustainability Hinges on One Critical Cash Flow Metric - 24/7 Wall St.
BMY: Growth Portfolio Carries The Case, Patent Cliffs Still Set The Limits
How Strong Phase 3 MRD Data for ZENBEXUS in Myeloma Could Impact Bristol Myers Squibb (BMY) Investors
Heart Failure Clinical Trial Drug Development Pipeline Expands with Contributions from 70+ Key Companies | DelveInsight | ABNewswire
Sugar-rich foods exacerbate antibiotic-induced microbiome disruption
Adrenocortical Carcinoma Market Poised for Sustained Growth Amid Advancements in Treatment and Clinical Innovation by 2036- DelveInsight | Orphagen Pharma, Corcept Therapeutics, Cytovation, Merck | ABNewswire
Bristol Myers Squibb (BMY) Reported 41.1% MRD Negative Responses In Phase 3 Trial
Could Bristol-Myers Squibb (BMY)'s New Myeloma Data Reshape its Growth Outlook?
A prospective observational study of treatment sequencing with regorafenib and FTD/TPI in metastatic colorectal cancer: The OSERO study
A synthetic lethal drug for microsatellite instability cancers
Acute Myocardial Infarction Market: Expanding Therapeutic Innovation, Secondary Prevention Strategies, and Emerging Pipeline Therapies to Drive Growth Through 2036 | ABNewswire
Myasthenia Gravis Clinical Trial Pipeline Gains Momentum: 28+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight | ABNewswire
Bristol-Myers Squibb (BMY) is Building its Next Growth Engine. Can It Replace Lost Revenue?
Promising Pharmaceutical Stocks To Research - September 28th - Zolmax
Lupin Receives Tentative Approval From U.S. FDA For Novel Apixaban Oral Suspension
Lupin Secures FDA Tentative Approval for Eliquis Generic, Targeting $3.3 Billion Market, ETPharma
Care Within Reach: How the Bristol Myers Squibb Foundation Is Strengthening Health Systems Across Africa
Lupin receives tentative approval for anticoagulant Apixaban from US FDA
Bristol Myers Squibb (NYSE:BMY) versus Cocrystal Pharma (NASDAQ:COCP) Financial Review - Markets Daily
Comparing Bristol Myers Squibb (NYSE:BMY) and Cocrystal Pharma (NASDAQ:COCP) - Stock Observer
Comparing Bristol Myers Squibb (NYSE:BMY) and Bausch Health Cos (NYSE:BHC) - Stock Observer
Global burden of venous thromboembolism: incidence and outcome estimates of deep-vein thrombosis and pulmonary embolism
317,360 Bristol Myers Squibb Company $BMY Shares Bought by Envestnet Asset Management Inc.
Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover?
Daratumumab ± pomalidomide maintenance after salvage autologous transplantation in relapsed multiple myeloma: a phase 2 study
Bristol Myers Squibb patents new NIK inhibitors
Zacks Research Upgrades Bristol Myers Squibb (NYSE:BMY) to "Strong-Buy" - Stock Observer
24,285 Bristol Myers Squibb Company $BMY Shares Acquired by Envestnet Portfolio Solutions Inc.
AI in Clinical Trials Market Set for Transformative Growth Through 2040, Unlocking Opportunities Across Trial Phases, Therapeutic Areas, End Users and Key Global Regions | Valuespectrum.com
Bristol Myers Squibb (BMY) Adds Restricted Pharmacy Path For New Myeloma Drug
Financial Contrast: Orion OYJ (OTCMKTS:ORINY) & Bristol Myers Squibb (NYSE:BMY) - Markets Daily
Leveraging Brazil's Health Networks for Early Lung Cancer Detection | Morningstar
Engineers Gate Manager LP Decreases Stake in Bristol Myers Squibb Company $BMY
Best Income Stocks to Buy for September 24th
Bristol Myers Squibb (NYSE:BMY) and Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Financial Survey - Zolmax
Crohns' Disease Clinical Trial Drug Development Pipeline Expands with Contributions from 90+ Key Companies | DelveInsight | ABNewswire
Bristol Myers Squibb (NYSE:BMY) versus Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Head to Head Contrast - Daily Political
State Street Corp Has $6.09 Billion Holdings in Bristol Myers Squibb Company $BMY
State Street Corp Has $6.09 Billion Stock Position in Bristol Myers Squibb Company $BMY - Stock Observer
Glioblastoma Market Set to Expand from USD 799 Million as New Therapies and a Robust Pipeline Advance Through 2034Glioblastoma (GBM) Market | ABNewswire
BristolMyers News
Gold Price Forecast Today and Next 30 Days: Can XAU/USD Extend Its Weekly Rebound?
ASML Stock Forecast 2026–2030: Can It Reach a $1 Trillion Valuation?
GE Vernova Stock Forecast & Analysis: Will Data-Centre Power and Grid Investment Fuel the Next Rally?
Samsung Electronics Stock Price Forecast 2026–2027: Can Record Q3 Profit Extend the AI Rally?
Latest news
Show more
Oil Price Today: Brent Slips Below $106 as Supply Risks Keep Markets on Edge
Bitcoin Price Today Falls Below $82,000 as ETF Outflows and High Yields Hit Crypto
Micron Stock Falls 3.88% Below $1,000 as CXMT Competition Raises Memory Pricing Concerns
Meta Stock Jumps 3.4% as Muse Wonder Takes Aim at OpenAI and Anthropic
Micron Stock Falls 3.9% as China’s CXMT Unveils Denser DRAM Technology
